Today, Jim Cramer - Mad Money and Larry Berman CFA, CMT, CTA commented about whether INTC-Q, T-T, VYM-N, DGRO, LUV-N, LYV-N, SHOP-N, BE-N, AMD-Q, HPQ-N, BMY-N, PG-N, AZN-N, RHI-N, ILMN-Q, CMA-N, ZION-N, WHR-N, XRAY-Q, VFC-N, BA-N, AAPL-Q are stocks to buy or sell.
Activist Elliott Management just took a big stake in this. Shares have fallen 50% in the past 3 years, and even lower than in March 2020 during the depths of the Covid shutdown. Elliott is a smart outfit and he agrees with their detailed assessment. LUV's underperformance is stunning during a travel boom and management's lack of action is off--they seem oblivious. Their had a bad Q1, and yet the CEO said they had a good quarter, despite the financial results. Really?? He agrees LUV needs a board anad management shake up and thorough review. Given Elliott, this is a buy.
Generally speaking, political shift to the right in Europe not a concern - however is something to note. Right leaning governments tend to simulate inflation as countries pursue protectionist strategies (cheaper goods not available), and less global trade. Upcoming CPI report (May) will give direction on US Fed policy regarding interest rates. If CPI data is higher than expected, will give less room on potential for interest rate cuts in the USA. Recent Canadian interest rate cuts putting pressure on Canadian dollar. Expecting another interest rate cut from the Bank of Canada.
Is overlooked in pharma. It boasts an amazing oncology business, including recent positive trial data on phase 2 and 3 lung cancer drugs, which could be breakthroughs. Shares have doubled in the last 5 years and has been climbing since 2016. Last April they delivered a blowout quarter with an earnings beat and a bullish forecast including a 8.5% compound annual growth rate based on doubling multi-billion drugs to 25 by 2030. Also, they are developing obesity drugs.